9/24/2026
NeuroThera and Clearmind expand U.S. patent portfolio
Collaboration focuses on LSD, ketamine, and ibogaine combinations.
Topic archive
neurothera labs inc.
5 stories
9/23/2026
Clearmind expands U.S. patent portfolio with new applications
Patent applications cover novel combinations of LSD, ketamine, and ibogaine.
9/23/2026
NeuroThera expands U.S. patent portfolio with ibogaine
Collaboration with Clearmind Medicine enhances therapeutic potential for mental health and substance use disorders.
9/23/2026
Clearmind Medicine files US patents for psychedelic combinations
New patent applications aim to enhance mental health treatments using LSD, ketamine, ibogaine.
9/23/2026
NeuroThera expands U.S. patent portfolio with Clearmind
New patent applications cover LSD, ketamine, and ibogaine combinations for mental health.